Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMTA5OE)

Drug Name
Azacitidine Drug Info
Synonyms
Azacitidina; Azacitidinum; Azacytidine; Ladakamycin; Mylosar; Vidaza; Mylo sar; Pharmion Brand of Azacitidine;A 2385; Antibiotic U 18496; U 18496; Wr 183027; Azacitidina [INN-Spanish]; Azacitidine [USAN:INN]; Azacitidinum [INN-Latin]; NS-17; Pyrimidine antimetabolite: inhibits nucleic acid replication; U-18496; Vidaz (TN); Vidaza (TN); WR-183027; Azacitidine (JAN/USAN/INN); S-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-(8CI); 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one; 5 AZC; 5 Azacytidine; 5-AC; 5-AZAC; 5-AZCR; 5-aza-CR; 5-azacitidine; 5-azacytidine; 5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine; 5AzaC
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
9444
ChEBI ID
CHEMBL1489
CAS Number
CAS 320-67-2
TTD Drug ID
D09FAZ
VARIDT Drug ID
DR00983
INTEDE Drug ID
DR0163

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Cysteine and methionine metabolism 2.18 0.00e+0 43/50 (86%) PSAT1;PHGDH;CTH;...
Ribosome biogenesis in eukaryotes 2.13 0.00e+0 52/108 (48.15%) GTPBP4;GNL3;RPP38;...
Glycine, serine and threonine metabolism 1.98 2.04e-3 31/40 (77.5%) PSAT1;PHGDH;CTH;...
RNA transport 1.96 3.07e-3 128/186 (68.82%) EIF4EBP1;EIF2S2;EIF1;...
Alanine, aspartate and glutamate metabolism 1.73 4.41e-2 27/37 (72.97%) ASNS;GFPT1;ASS1;...
Mineral absorption -1.76 8.23e-3 48/60 (80%) MT2A;ATP1B2;CLCN2;...
Regulation of lipolysis in adipocytes -1.76 8.47e-3 52/55 (94.55%) GNAS;PTGS1;PTGER3;...
Vibrio cholerae infection -1.77 8.43e-3 44/50 (88%) ATP6V0A4;PLCG1;KCNQ1;...
ECM-receptor interaction -1.79 7.89e-3 80/88 (90.91%) ITGB8;COL4A5;ITGB4;...
Fatty acid degradation -1.81 7.68e-3 40/43 (93.02%) ACSL1;ACADS;ADH6;...
Bile secretion -1.85 3.73e-3 68/90 (75.56%) GNAS;CFTR;ATP1A1;...
Lysosome -1.86 3.33e-3 115/128 (89.84%) PPT2;GLB1;CTSS;...
Valine, leucine and isoleucine degradation -1.87 2.32e-3 42/48 (87.5%) ACAA1;AOX1;EHHADH;...
Fatty acid elongation -1.88 2.42e-3 19/27 (70.37%) PPT2;HACD3;HADHA;...
Complement and coagulation cascades -1.88 2.54e-3 76/85 (89.41%) F2;MASP1;PLAT;...
Fructose and mannose metabolism -1.89 2.66e-3 30/33 (90.91%) PFKM;KHK;SORD;...
Metabolism of xenobiotics by cytochrome P450 -1.89 2.80e-3 49/77 (63.64%) HPGDS;CYP2C9;GSTA3;...
PPAR signaling pathway -1.89 2.96e-3 66/74 (89.19%) APOC3;ACOX3;PLTP;...
Mucin type O-glycan biosynthesis -1.90 2.35e-3 20/36 (55.56%) GALNT7;GALNT14;ST6GALNAC2;...
Arrhythmogenic right ventricular cardiomyopathy -1.90 2.50e-3 70/77 (90.91%) ITGB8;ITGB4;ITGB6;...
Antigen processing and presentation -1.92 2.66e-3 60/78 (76.92%) HLA-G;HLA-B;HLA-DQB1;...
Drug metabolism -1.93 2.85e-3 78/151 (51.66%) DPYS;ADH6;GSTP1;...
Propanoate metabolism -1.94 3.07e-3 30/34 (88.24%) ACOX3;HADHA;ACOX1;...
Synthesis and degradation of ketone bodies -1.95 3.33e-3 9/10 (90%) BDH1;ACAT2;HMGCS1
Oxidative phosphorylation -1.96 2.42e-3 93/133 (69.92%) SDHB;NDUFS6;ATP5F1E;...
Pentose phosphate pathway -2.00 1.33e-3 25/30 (83.33%) ALDOB;PGD;G6PD;...
Fat digestion and absorption -2.00 1.48e-3 35/43 (81.4%) MTTP;AGPAT2;APOA1;...
Diabetic cardiomyopathy -2.02 1.66e-3 162/203 (79.8%) ATP5F1B;CYBB;NDUFA10;...
Butanoate metabolism -2.03 1.90e-3 23/28 (82.14%) HADHA;BDH2;ACSM3;...
Aldosterone-regulated sodium reabsorption -2.03 2.22e-3 34/37 (91.89%) HSD11B2;PIK3CB;INSR;...
Terpenoid backbone biosynthesis -2.05 2.66e-3 18/22 (81.82%) MVK;ICMT;MVD;...
Cholesterol metabolism -2.12 0.00e+0 44/50 (88%) ABCG5;SOAT2;APOC1;...
Carbohydrate digestion and absorption -2.15 0.00e+0 37/47 (78.72%) ATP1B2;PLCB4;ATP1A1;...
Biosynthesis of unsaturated fatty acids -2.16 0.00e+0 21/27 (77.78%) ACOX3;HACD3;HSD17B12;...
Steroid biosynthesis -2.41 0.00e+0 19/20 (95%) LBR;HSD17B7;TM7SF2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Bone marrow
Neuroblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SH-SY5Y CVCL_0019 Homo sapiens 0.04uM - 10uM 24H
SK-N-SH CVCL_0531 Homo sapiens 0.04uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Normal (Epithelial)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HME1 CVCL_2950 Homo sapiens 0.04uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
SNU-407 CVCL_5004 Homo sapiens 1.11uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 3.33uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 0.04uM - 10uM 24H
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
A549/Asc-1 CVCL_YA87 Homo sapiens 0.04uM - 10uM 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 3.33uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 3.33uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 0.37uM - 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
SK-L CVCL_1699 Homo sapiens 0.04uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H